menu
    • menu

    Company profile for Iontas

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    IONTAS is a biotechnology company focused on the development of novel antibody therapeutics. It employs its proven expertise in all key areas of therapeutic antibody discovery and development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Iontasunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Unit 2, \nIconix Park, London Road, \nPampisford, \nCambridgeshire CB22 3EG
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iontas.co.uk/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
    IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial

    29 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210629005557/en

    BUSINESSWIRE
    29 Jun 2021
    Share Share
    IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies
    IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

    22 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210322005714/en

    BUSINESSWIRE
    22 Mar 2021
    Share Share
    IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies
    IONTAS Identifies Novel SARS-CoV-2 Neutralising Antibodies

    22 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210322005714/en/IONTAS-Identifies-Novel-SARS-CoV-2-Neutralising-Antibodies#:~:text=A%20sub%2Dset%20of%20the,SARS%2DCoV%2D1%20virus.

    BUSINESSWIRE
    22 Mar 2021
    Share Share
    IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell
    IONTAS and FairJourney Biologics Enter Antibody Discovery Agreement With Quell

    08 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210308005364/en

    BUSINESSWIRE
    08 Mar 2021
    Share Share
    Iontas Enters Licensing Agreement with Bristol Myers Squibb
    Iontas Enters Licensing Agreement with Bristol Myers Squibb

    15 Oct 2020

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2020-10-14/iontas-enters-licensing-agreement-with-bristol-myers-squibb/

    CONTRACTPHARMA
    15 Oct 2020
    Share Share
    IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets
    IONTAS Announces a New Collaboration to Identify Novel Immunotherapy Targets

    07 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200507005424/en

    BUSINESSWIRE
    07 May 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search